Intra-Dosage Form Coatings and Applications Thereof
The present disclosure relates to coating formulations for use in multi-ingredient dosage forms comprising vitamin C and/or choline. The coating formulations surround the vitamin C and/or the choline in a multi-ingredient dosage form, which prevents spotting of the dosage forms.
1 . A coating formulation comprising shellac, wherein the coating formulation coats at least one active ingredient in a multi-ingredient dosage form.
2 . The coating formulation of claim 1 , wherein the at least one active ingredient has a concentration of between about 50.0 mass % to about 95.0 mass % relative to the total mass of the at least one active ingredient and the coating formulation.
3 . The coating formulation of claim 1 , wherein the at least one active ingredient comprises vitamin C.
4 . The coating formulation of claim 3 , wherein the vitamin C is ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, or silver ascorbate, or a combination thereof.
5 . The coating formulation of claim 3 , wherein the vitamin C is present in an amount from about 50 mass % to about 95 mass % relative to the combined mass of the vitamin C and the coating formulation.
6 . The coating formulation of claim 1 , wherein the at least one active ingredient comprises choline.
7 . The coating formulation of claim 6 , wherein the choline is choline chloride, choline bitartrate, phosphatidyl choline, choline dihydrogen citrate, alpha glycerylphosphorylcholine, cytidine diphosphatecholine, choline folate, an ester of choline with DHA, an ester of choline with 3-methyl-2-hexenoic acid (MHA), an ester of choline with medium chain triglycerides, or an ester of choline with a fatty acid, or a combination thereof.
8 . The coating formulation of claim 6 , wherein the choline is present in an amount from about 50 mass % to about 95 mass % relative to the combined mass of the choline and the coating formulation.
9 . The coating formulation of claim 1 , wherein the shellac is present in an amount from about 1 mass % to about 50 mass % relative to the combined mass of the at least one active ingredient and the coating formulation.
10 . The coating formulation of claim 1 , wherein the coating formulation further comprises a silicate, cellulose or a derivative thereof, starch.
11 . The coating formulation of claim 10 , wherein the silicate is silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, or silicified microcrystalline cellulose, or a combination thereof.
12 . The coating formulation of claim 10 , wherein the silicate is present in the coating formulation in an amount from about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.
13 . The coating formulation of claim 11 , wherein the silicon dioxide is colloidal silicon dioxide or fumed silica.
14 . (canceled)
15 . The coating formulation of claim 10 , wherein the cellulose or a derivative thereof is microcrystalline cellulose, powdered cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hypromellose, or carboxymethylcellulose, or a combination thereof.
16 . The coating formulation of claim 15 , wherein the cellulose or a derivative thereof is hydroxypropylcellulose, microcrystalline cellulose, or ethylcellulose.
17 . The coating formulation of claim 16 , wherein (i) the hydroxypropylcellulose or ethylcellulose is present in the coating formulation in an amount from about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient or (ii) the microcrystalline cellulose is present in the coating formulation in an amount from about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient and second active ingredient.
18 - 22 . (canceled)
23 . The coating formulation of claim 10 , wherein the starch is maize starch, potato starch, rice starch, wheat starch, or tapioca starch, or a combination thereof.
24 . The coating formulation of claim 23 , wherein the starch is present in the coating formulation in an amount from about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.
25 . A multi-ingredient dosage form, the dosage form comprising:
at least one active ingredient; and
the coating formulation of claim 1 ,
wherein the coating formulation coats the at least one active ingredient.
26 . (canceled)
27 . The multi-ingredient dosage form of claim 25 , wherein the vitamin C and/or choline is present in the dosage form in an amount of about 1 mg to about 2000 mg.
28 - 33 . (canceled)
34 . The multi-ingredient dosage form claim 25 , wherein:
(i) the at least one active ingredient comprises vitamin C and choline, and wherein the choline is not coated by the coating formulation; or
(ii) the at least one active ingredient comprises choline and the dosage form further comprises vitamin C, wherein the vitamin C is not coated by the coating formulation; or
(iii) the at least one active ingredient comprises vitamin C and the dosage form further comprises choline, wherein the choline is not coated by the coating formulation.
35 - 54 . (canceled)
55 . The multi-ingredient dosage form of claim 25 , wherein the multi-ingredient dosage form has little spotting after storage for about 18, about 60, or about 120 days at 25° C. and 20% relative humidity, 45° C. and 20% relative humidity, 25° C. and 30% relative humidity, or 45° C. and 30% relative humidity.
56 - 66 . (canceled)
67 . The multi-ingredient dosage form of claim 25 , comprising:
choline;
vitamin C; and
a coating formulation comprising shellac,
wherein the coating formulation coats the choline or vitamin C.
68 . (canceled)
69 . The multi-ingredient dosage form of claim 25 , comprising:
choline, wherein the choline is coated by a first coating formulation comprising shellac; and
vitamin C, wherein the vitamin C is coated by a second coating formulation comprising shellac.
70 . A method of preventing black spotting on a dosage form, the method comprising:
providing an active ingredient comprising at least one of vitamin C and choline;
coating the active ingredient in a coating formulation comprising shellac; and
including the active ingredient coated in the coating formulation in a dosage form.
71 - 100 . (canceled)